Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients Jan. 17, 2024 7:01 AM ET Acurx Pharmaceuticals, Inc. (ACXP) ...
STATEN ISLAND, N.Y., Jan. 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results